Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100P1F0
Period2022-01-01 → 2022-06-30
Filed2022-08-15
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥6.5bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥2.6bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥682m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥522m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥941m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥509m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥745m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥309m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥35.3bnat 2022-06-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥13.5bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.1bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥17.9bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥2.9bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.32021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.782021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.732021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥10.592021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.9%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-06-30¥390m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-06-30¥1.1bn
—segment totalrevenue2021-01-01 → 2021-06-30¥6.5bn
—segment totalrevenue external2021-01-01 → 2021-06-30¥6.5bn
—segment totalsegment profit2021-01-01 → 2021-06-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Proceeds from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration1319377000JPY
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration86425000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration2962850000JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration－JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-47944000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-56269000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-95000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration－JPY
Refund from non controlling interest fin cf IFRSPrior1YTDDuration-524447000JPY
Refund from non controlling interest fin cf IFRSCurrentYTDDuration－JPY
Dividends paid fin cf IFRSPrior1YTDDuration-150838000JPY
Dividends paid fin cf IFRSCurrentYTDDuration－JPY
Other fin cf IFRSPrior1YTDDuration-25611000JPY
Other fin cf IFRSCurrentYTDDuration-11022000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration2906178000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-267292000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration498300000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1489531000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration3498457000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration114694000JPY
Cash and cash equivalents IFRSPrior2YearInstant10322664000JPY
Cash and cash equivalents IFRSPrior1YearInstant14352133000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant13821122000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant14466828000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember5457052000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1008123000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember6465175000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration6465175000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember5457052000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember1008123000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember6465175000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue IFRSPrior1YTDDuration6465175000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember1065659000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember389969000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1455628000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration1455628000JPY
Finance income IFRSPrior1YTDDuration32809000JPY
Finance costs IFRSPrior1YTDDuration290762000JPY
Profit loss before tax IFRSPrior1YTDDuration1197676000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember6989504000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass